Bansal Reema, Beke Nikhil, Sharma Aman, Gupta Amod
Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
BMJ Case Rep. 2013 Sep 6;2013:bcr2013200255. doi: 10.1136/bcr-2013-200255.
A 43-year-old woman with tubercular choroidal granuloma showed poor response to conventional first-line four-drug antitubercular therapy (ATT) and corticosteroids. A therapeutic trial with intravitreal bevacizumab (1.25 mg in 0.05 mL) injections as an adjunct to ATT and corticosteroids led to a prompt initial regression of granuloma with restoration of visual acuity that was sustained for almost 2 years. A subsequent recurrence of the same lesion with evidence of enhanced vascularity was treated with intravitreal bevacizumab alone, that led to a complete regression of the granuloma with no recurrence until 1 year of follow-up.
一名患有结核性脉络膜肉芽肿的43岁女性，对传统的一线四联抗结核治疗（ATT）和皮质类固醇治疗反应不佳。一项将玻璃体内注射贝伐单抗（0.05 mL中含1.25 mg）作为ATT和皮质类固醇辅助治疗的试验，使肉芽肿迅速初步消退，视力恢复，并持续了近2年。随后，同一病变复发且有血管增多的迹象，单独使用玻璃体内注射贝伐单抗进行治疗，肉芽肿完全消退，直至随访1年无复发。
